Organization Led By Former VP Pence Backs Fr. Emmanuel Lemelson in Legal Fight 

Organization Led By Former VP Mike Pence, backs Fr. Emmanuel Lemelson in Legal Fee Battle After Defeating Unprecedented SEC Charges

New York, NY (December 4, 2024) – Today, Advancing American Freedom, led by the 48th Vice President of the United States, Michael Pence, along with The Southern Policy Law Institute and more than two dozen other organizations, joined Fr. Emmanuel Lemelson and his legal team in fighting to recover attorney’s fees and costs stemming from his 2021 landmark victory over fraudulent SEC charges.

Read: Not Liable. The Unlawful Prosecution of Fr. Emmanuel Lemelson

In July 2024, the U.S. District Court affirmed Lemelson as a “prevailing party” in his nearly decade-long fight against the SEC. This followed a November 2021 trial in which a federal jury overwhelmingly rejected the agency’s baseless allegations. The action seeks to hold the SEC accountable for the substantial costs incurred during the protracted legal battle.

“The SEC, a tool of the radical left’s policy agenda, is a corrupt, captured regulator,” said Lemelson. “Our fight to recover millions in legal fees isn’t over. Sadly, taxpayers won’t reclaim the millions squandered on a spiteful case aimed at silencing a whistleblower and shielding fraud at Ligand Pharmaceuticals (NASDAQ: LGND), which fleeced taxpayers, led to billions in investor losses and put patients at risk,” Lemelson continued.

See previous release here

See SEC vs. Fr. Emmanuel Lemelson, No. 24-1754

Brief of Amici Curiae Advancing American Freedom In Support of Fr. Emmanuel Lemelson by amvona on Scribd

Letters to Congress Regarding Ligand:

• December 19, 2016 – Lantern Foundation Founder Urges Senate Committee to Commence Investigation into Ligand Pharmaceuticals
• July 13, 2018 – Rev. Fr. Emmanuel Lemelson Calls on Congress, Office of Inspector General to Investigate SEC Failures 

The Ligand Research Reports:

• June 14, 2014 – Ligand Pharmaceuticals – Severe competitive threat to key royalty program and “going concern” risk drive 100 percent downside
• July 3, 2014 – Ligand Pharmaceuticals (NASDAQ: LGND): Appendix
• August 4, 2014 – Update: Lemelson Capital Further Increases Short Stake in Ligand Pharmaceuticals (NASDAQ: LGND) as LGND EPS Plunges 76 percent in Q2 2014
• August 14, 2014 – Lemelson Capital Says Ligand Pharmaceuticals’ (NASDAQ: LGND) $225M Debt Issuance Solidifies Company’s Insolvency, Substantially Raises Specter of Bankruptcy
• August 22, 2014 – Ligand Pharmaceuticals (NASDAQ: LGND): Institutional holders wasting no time dumping stock in response to mounting insolvency and bankruptcy risks

The Ligand Interviews:

• Rev. Emmanuel Lemelson of Lemelson Capital Management – #PreMarket Prep for June 19, 2014 
• Rev. Emmanuel Lemelson, CIO of Lemelson Capital Management – #PreMarket Prep for August 13, 2014
• Rev Emmanuel Lemelson, CIO of Lemelson Capital Management – #PreMarket Prep for September 16, 2014 
• Rev. Emmanuel Lemelson, CIO of Lemelson Capital Management – #PreMarket Prep for October 16, 2014
• Rev. Emmanuel Lemelson, Lemelson Capital Management – #PreMarket Prep for November 18, 2014
• Rev. Emmanuel Lemelson, CIO of Lemelson Capital Management – #PreMarket Prep for February 20, 2015
• Rev. Emmanuel Lemelson, Lemelson Capital Management CIO – #PreMarket Prep for March 24, 2015
• Rev. Emmanuel Lemelson, CIO of Lemelson Capital Management – #PreMarket Prep for April 27, 2015
• Rev. Emmanuel Lemelson, CIO of Lemelson Capital Management – #PreMarket Prep for June 5, 2015
• Rev. Emmanuel Lemelson, CIO of Lemelson Capital Management – #PreMarket Prep for August 12, 2015
• Listen to Fr. Emmanuel live discussing The Amvona Fund, LP and his recent letter to the US Senate